Cargando…
Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
IMPORTANCE: COVID-19 and seasonal influenza vaccines were previously given separately, although their coadministration is warranted for vaccination adherence. Limited data on their coadministration have been published. OBJECTIVE: To compare the reactogenicity and immunogenicity of COVID-19 and influ...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492184/ https://www.ncbi.nlm.nih.gov/pubmed/37682571 http://dx.doi.org/10.1001/jamanetworkopen.2023.32813 |
_version_ | 1785104197394366464 |
---|---|
author | Gonen, Tal Barda, Noam Asraf, Keren Joseph, Gili Weiss-Ottolenghi, Yael Doolman, Ram Kreiss, Yitshak Lustig, Yaniv Regev-Yochay, Gili |
author_facet | Gonen, Tal Barda, Noam Asraf, Keren Joseph, Gili Weiss-Ottolenghi, Yael Doolman, Ram Kreiss, Yitshak Lustig, Yaniv Regev-Yochay, Gili |
author_sort | Gonen, Tal |
collection | PubMed |
description | IMPORTANCE: COVID-19 and seasonal influenza vaccines were previously given separately, although their coadministration is warranted for vaccination adherence. Limited data on their coadministration have been published. OBJECTIVE: To compare the reactogenicity and immunogenicity of COVID-19 and influenza vaccinations administered together with those of COVID-19 vaccination alone. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study included health care workers at a large tertiary medical center in Israel who received the Influvac Tetra (Abbott) influenza vaccine (2022/2023), the Omicron BA.4/BA.5–adapted bivalent (Pfizer/BioNTech) vaccine, or both. Vaccination began in September 2022, and data were collected until January 2023. Vaccines were offered to all employees and were coadministered or given separately. Adverse reaction questionnaires were sent, and serologic samples were also collected. EXPOSURES: Receiving COVID-19 vaccine, influenza vaccine, or both. MAIN OUTCOMES AND MEASURES: The main outcomes for the reactogenicity analysis were symptoms following vaccine receipt, assessed by a digital questionnaire: any local symptoms; fever; weakness or fatigue; any systemic symptoms; and their duration. The immunogenicity analysis’ outcome was postvaccination anti-spike IgG titer. RESULTS: This study included 2 cohorts for 2 separate analyses. The reactogenicity analysis included 588 participants (of 649 questionnaire responders): 85 in the COVID-19 vaccine–alone group (median [IQR] age, 71 [58-74] years; 56 [66%] female); 357 in the influenza vaccine–alone group (median [IQR] age, 55 [40-65] years; 282 [79%] female); and 146 in the coadministration group (median [IQR] age, 61 [50-71] years; 81 [55%] female). The immunogenicity analysis included 151 participants: 74 participants in the COVID-19 vaccine group (median [IQR] age, 67 [56-73] years; 45 [61%] female) and 77 participants in the coadministration group (median [IQR] age, 60 [49-73] years; 42 [55%] female). Compared with COVID-19 vaccination alone, the risk of systemic symptoms was similar in the coadministration group (odds ratio, 0.82; 95% CI, 0.43-1.56). Geometric mean titers in the coadministration group were estimated to be 0.84 (95% CI, 0.69-1.04) times lower than in the COVID-19 vaccine–alone group. CONCLUSIONS AND RELEVANCE: In this cohort study of health care workers who received a COVID-19 vaccine, an influenza vaccine, or both, coadministration was not associated with substantially inferior immune response or to more frequent adverse events compared with COVID-19 vaccine administration alone, supporting the coadministration of these vaccines. |
format | Online Article Text |
id | pubmed-10492184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-104921842023-09-10 Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines Gonen, Tal Barda, Noam Asraf, Keren Joseph, Gili Weiss-Ottolenghi, Yael Doolman, Ram Kreiss, Yitshak Lustig, Yaniv Regev-Yochay, Gili JAMA Netw Open Original Investigation IMPORTANCE: COVID-19 and seasonal influenza vaccines were previously given separately, although their coadministration is warranted for vaccination adherence. Limited data on their coadministration have been published. OBJECTIVE: To compare the reactogenicity and immunogenicity of COVID-19 and influenza vaccinations administered together with those of COVID-19 vaccination alone. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study included health care workers at a large tertiary medical center in Israel who received the Influvac Tetra (Abbott) influenza vaccine (2022/2023), the Omicron BA.4/BA.5–adapted bivalent (Pfizer/BioNTech) vaccine, or both. Vaccination began in September 2022, and data were collected until January 2023. Vaccines were offered to all employees and were coadministered or given separately. Adverse reaction questionnaires were sent, and serologic samples were also collected. EXPOSURES: Receiving COVID-19 vaccine, influenza vaccine, or both. MAIN OUTCOMES AND MEASURES: The main outcomes for the reactogenicity analysis were symptoms following vaccine receipt, assessed by a digital questionnaire: any local symptoms; fever; weakness or fatigue; any systemic symptoms; and their duration. The immunogenicity analysis’ outcome was postvaccination anti-spike IgG titer. RESULTS: This study included 2 cohorts for 2 separate analyses. The reactogenicity analysis included 588 participants (of 649 questionnaire responders): 85 in the COVID-19 vaccine–alone group (median [IQR] age, 71 [58-74] years; 56 [66%] female); 357 in the influenza vaccine–alone group (median [IQR] age, 55 [40-65] years; 282 [79%] female); and 146 in the coadministration group (median [IQR] age, 61 [50-71] years; 81 [55%] female). The immunogenicity analysis included 151 participants: 74 participants in the COVID-19 vaccine group (median [IQR] age, 67 [56-73] years; 45 [61%] female) and 77 participants in the coadministration group (median [IQR] age, 60 [49-73] years; 42 [55%] female). Compared with COVID-19 vaccination alone, the risk of systemic symptoms was similar in the coadministration group (odds ratio, 0.82; 95% CI, 0.43-1.56). Geometric mean titers in the coadministration group were estimated to be 0.84 (95% CI, 0.69-1.04) times lower than in the COVID-19 vaccine–alone group. CONCLUSIONS AND RELEVANCE: In this cohort study of health care workers who received a COVID-19 vaccine, an influenza vaccine, or both, coadministration was not associated with substantially inferior immune response or to more frequent adverse events compared with COVID-19 vaccine administration alone, supporting the coadministration of these vaccines. American Medical Association 2023-09-08 /pmc/articles/PMC10492184/ /pubmed/37682571 http://dx.doi.org/10.1001/jamanetworkopen.2023.32813 Text en Copyright 2023 Gonen T et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Original Investigation Gonen, Tal Barda, Noam Asraf, Keren Joseph, Gili Weiss-Ottolenghi, Yael Doolman, Ram Kreiss, Yitshak Lustig, Yaniv Regev-Yochay, Gili Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines |
title | Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines |
title_full | Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines |
title_fullStr | Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines |
title_full_unstemmed | Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines |
title_short | Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines |
title_sort | immunogenicity and reactogenicity of coadministration of covid-19 and influenza vaccines |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492184/ https://www.ncbi.nlm.nih.gov/pubmed/37682571 http://dx.doi.org/10.1001/jamanetworkopen.2023.32813 |
work_keys_str_mv | AT gonental immunogenicityandreactogenicityofcoadministrationofcovid19andinfluenzavaccines AT bardanoam immunogenicityandreactogenicityofcoadministrationofcovid19andinfluenzavaccines AT asrafkeren immunogenicityandreactogenicityofcoadministrationofcovid19andinfluenzavaccines AT josephgili immunogenicityandreactogenicityofcoadministrationofcovid19andinfluenzavaccines AT weissottolenghiyael immunogenicityandreactogenicityofcoadministrationofcovid19andinfluenzavaccines AT doolmanram immunogenicityandreactogenicityofcoadministrationofcovid19andinfluenzavaccines AT kreissyitshak immunogenicityandreactogenicityofcoadministrationofcovid19andinfluenzavaccines AT lustigyaniv immunogenicityandreactogenicityofcoadministrationofcovid19andinfluenzavaccines AT regevyochaygili immunogenicityandreactogenicityofcoadministrationofcovid19andinfluenzavaccines |